Giane35

Giane is a combined hormonal preparation containing an anti-androgen (cyproterone acetate) and an estrogen (ethinyl estradiol), indicated as follows:

• Established/guideline-supported use: Treatment of moderate to severe androgen-sensitive acne (with or without seborrhoea) and/or hirsutism in women of reproductive age, when topical treatment and/or systemic antibiotic therapy have proven ineffective.
• Adjunct/commonly used off-label context: Management of clinical signs of hyperandrogenism (acne, hirsutism, mild androgenic alopecia) associated with polycystic ovary syndrome (PCOS), used as part of an overall management plan rather than as a stand-alone PCOS therapy.

Because Giane also suppresses ovulation, women taking it for the above indications receive a secondary contraceptive effect while on treatment; however, current safety-driven prescribing guidance in many regulatory contexts specifically advises that Giane is not indicated for use as a standard first-line contraceptive alone and should be reserved for the androgen-related indications above, given its thromboembolic risk profile (see Precautions and Warnings). It is not indicated for use in women without clinical signs of androgen excess.

Each sugar-coated/film-coated tablet of Cyproterone Acetate + Ethinyl Estradiol typically contains Cyproterone Acetate 2 mg and Ethinyl Estradiol 35 microgram (0.035 mg) as active ingredients, supplied in calendar blister packs of 21 active tablets (some brands include additional inactive/placebo tablets to support a continuous daily-pill habit). Excipients vary by manufacturer.

Giane is an oral combination product pairing cyproterone acetate, a potent anti-androgen with progestogenic activity, with ethinyl estradiol, a synthetic estrogen. It is used specifically in women of reproductive age to treat androgen-driven skin and hair symptoms — chiefly moderate-to-severe acne and hirsutism, including that associated with polycystic ovary syndrome (PCOS) — that have not responded adequately to topical or antibiotic treatment. While it suppresses ovulation and provides a secondary contraceptive effect during use, it is prescribed and dosed as a therapeutic anti-androgen/estrogen combination rather than as a routine first-choice contraceptive, and treatment duration is intentionally limited and periodically reassessed by a physician.

Giane belongs to the therapeutic class of anti-androgen and estrogen combination preparations (combined hormonal antiandrogenic agents), used in the management of androgen-related dermatological conditions in women.

Cyproterone Acetate + Ethinyl Estradiol combines two complementary hormonal actions:

• Cyproterone acetate is a potent anti-androgen that competitively blocks androgen receptors in target tissues (skin, sebaceous glands, hair follicles), reducing the peripheral effects of testosterone and dihydrotestosterone that drive sebum overproduction, acne, and hirsutism. It also has progestogenic and antigonadotropic activity, which suppresses pituitary luteinizing hormone (LH) release and reduces ovarian androgen production.
• Ethinyl estradiol suppresses pituitary follicle-stimulating hormone (FSH) and LH secretion (inhibiting ovulation) and increases hepatic synthesis of sex hormone-binding globulin (SHBG), which binds circulating free testosterone and further lowers biologically active androgen levels.

Together, these actions reduce circulating and tissue-level androgen activity, improving acne and hirsutism over a course of several months, while also regulating the menstrual cycle and suppressing ovulation for the duration of use.

Tablets of Giane should be swallowed whole with water, in the order indicated on the blister pack, at roughly the same time every day to maintain steady hormone levels and menstrual cycle control. Tablets may be taken with or without food. Do not skip the 7-day tablet-free interval unless specifically instructed by a physician.

Giane has clinically significant interactions with drugs that induce or inhibit hepatic enzymes (mainly CYP3A4):

• Enzyme-inducing drugs (e.g., rifampicin, certain anticonvulsants such as phenytoin, carbamazepine, barbiturates, oxcarbazepine, topiramate, and the herbal product St. John's Wort, as well as certain antiretrovirals) can lower circulating hormone levels, reducing efficacy of Giane and increasing the risk of breakthrough bleeding or, for its secondary contraceptive effect, contraceptive failure; additional non-hormonal precautions are advised during and for a period after co-administration.
• Strong enzyme-inhibiting drugs may increase circulating estrogen/progestogen levels, potentially increasing the risk of hormone-related adverse effects.
• Certain direct-acting antiviral combinations used for hepatitis C (e.g., ombitasvir/paritaprevir/ritonavir with or without dasabuvir; glecaprevir/pibrentasvir; sofosbuvir/velpatasvir/voxilaprevir) can cause clinically significant elevations in liver enzymes when co-administered with ethinyl estradiol-containing products; Giane should be stopped and an alternative method used before starting such therapy.

Patients should inform their physician of all medicines, herbal products, and supplements they are taking before starting Giane.

The most commonly reported side effects of Giane (occurring in ≥1% of users) include:

• Nausea and abdominal pain
• Headache
• Weight increase
• Depressed mood or altered mood
• Breast pain or tenderness
• Menstrual changes: reduced menstrual flow, missed periods, intermenstrual (breakthrough) bleeding, or amenorrhea after stopping treatment

Serious but less common effects include venous and arterial thromboembolic events, hypertension, hepatic tumors, meningioma (with prolonged/cumulative dosing), chloasma (facial skin pigmentation), and depression, which has rarely been associated with suicidal ideation (see Precautions and Warnings for management of these risks). Patients should seek prompt medical attention for symptoms such as leg swelling/pain, chest pain, sudden breathlessness, severe headache, visual disturbance, or one-sided weakness.

Pregnancy: Giane is contraindicated in known or suspected pregnancy. Pregnancy must be excluded before starting treatment, and the medicine should be stopped immediately if pregnancy occurs or is suspected during treatment; a physician should be consulted promptly, as animal data suggest a theoretical risk of feminization of a male fetus if cyproterone acetate is taken during early gestation. Giane should be used only if clearly indicated and never during pregnancy.

Lactation: Giane is contraindicated during breastfeeding. It can reduce breast milk volume and alter its composition, and hormone components pass into breast milk; women should not take Giane until they have fully weaned their infant, and should discuss alternative, breastfeeding-compatible options with their physician in the meantime.

Thromboembolic risk (venous and arterial): Giane carries an increased risk of venous thromboembolism (VTE) compared with non-use, and several regulatory reviews have specifically flagged that cyproterone-acetate-containing combined hormonal preparations carry a higher VTE risk than combined hormonal contraceptives containing certain other progestins (approximately 1.5–2 times higher than levonorgestrel-containing products in comparative data). VTE can rarely be fatal. Arterial thromboembolic events (heart attack, stroke) are also more likely with risk factors such as smoking (especially over age 35), hypertension, diabetes, dyslipidemia, obesity (BMI over 30 kg/m²), migraine, valvular or arrhythmic heart disease, family history of thromboembolism, or prolonged immobilization/major surgery. Risk factors should be assessed before starting and periodically during use, and Giane should be stopped well before planned major surgery or periods of prolonged immobilization.

Meningioma: A cumulative dose- and duration-dependent association between cyproterone acetate and meningioma has been observed; if meningioma is diagnosed, Giane must be permanently discontinued.

Hepatic effects: Rare cases of benign and malignant liver tumors and other hepatic disorders have been reported with cyproterone acetate, especially with higher doses or prolonged use; unexplained abdominal pain, hepatomegaly, or signs of intra-abdominal bleeding warrant urgent evaluation and discontinuation.

Breast cancer: Long-term use of combined hormonal preparations is associated with a small increase in the relative risk of breast cancer diagnosis, which appears to decline after stopping; this should be discussed as part of the overall risk-benefit assessment.

Mood effects: Depression and mood changes, rarely including suicidal ideation, have been reported; patients with a history of depression should be monitored, and the medicine should be reassessed promptly if significant mood symptoms occur.

Not for routine first-line contraception: Given its thromboembolic risk profile, Giane should be reserved for its androgen-related dermatological indications rather than used as a first-choice standard contraceptive, consistent with current safety-driven prescribing guidance in several regulatory settings.

Other: Use with caution in women with hypertension, diabetes, hyperlipidemia, or a tendency to chloasma (sun exposure can worsen chloasma). Periodic medical review, including blood pressure checks, is recommended throughout treatment.

Overdose with Giane may cause nausea, vomiting, and, in females, withdrawal-type vaginal bleeding. There is no specific antidote. Anyone who has taken more than the prescribed amount, especially children with accidental ingestion, should seek immediate medical attention or contact a poison control center/emergency services; treatment is supportive and symptomatic based on clinical presentation. Do not attempt unsupervised home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Hepatic impairment: Contraindicated in severe hepatic disease, hepatic tumors, or persistently abnormal liver function (see Contraindications); use with caution and close monitoring in milder hepatic impairment.

Renal impairment: No specific dose adjustment is established; general precautions for combined hormonal preparations apply.

Elderly: Not applicable; Giane is used only in women of reproductive age and is not indicated after menopause.

Adolescents: May be used only after menarche, when clinically indicated for androgen-related acne/hirsutism; see Pediatric Uses.

Smokers over 35 years: Increased thromboembolic risk; use is generally avoided in this group (see Precautions and Warnings).

Improvement in acne or hirsutism with Giane typically requires a minimum of 3 to 4 treatment cycles (approximately 3–4 months) before benefit can be properly assessed, since skin and hair growth cycles respond slowly to hormonal change. Treatment should be periodically reviewed by a physician (commonly every 3–6 months), weighing continued benefit against cumulative thromboembolic, hepatic, and other risks. Once symptoms have resolved, Giane is typically continued for a further few cycles (often 3–4) to consolidate improvement and then stopped, with an alternative, lower-risk contraceptive method used afterward if contraception is still needed, since Giane is not intended for long-term routine contraceptive use.

Cyproterone Acetate + Ethinyl Estradiol belongs to the following drug classes: anti-androgens (cyproterone acetate); synthetic estrogens (ethinyl estradiol); combined hormonal antiandrogenic preparations.

Cyproterone Acetate + Ethinyl Estradiol works through the combined action of an anti-androgen and an estrogen: cyproterone acetate blocks androgen receptors at the skin and hair follicle level and reduces ovarian/adrenal androgen output via antigonadotropic activity, while ethinyl estradiol suppresses ovulation and raises SHBG to further lower free testosterone. The net effect is reduced androgenic stimulation of sebaceous glands and hair follicles, improving acne and hirsutism, along with cycle regulation and ovulation suppression for the duration of treatment.

X

Giane is indicated only in females of reproductive age after menarche; it is not used before menarche, and safety and efficacy in premenarchal children have not been established. There is no approved use in male patients. Adolescent girls after menarche with androgen-related acne or hirsutism unresponsive to topical/antibiotic therapy may be treated under close medical supervision, with the same contraindications, precautions, and periodic reassessment that apply to adult women.